November 19, 2021 7:36am

Another weak aftermarket could highlight Friday’s exit lights

Pre-open indications: 5 SELLs, 1 BUY and 1 Pump (or No Promote)

If you’re looking for sector intel, ideas and facts or Insight in a volatile climate, RMi defines the extenuating factors of share pricing!

Remember that overnight and pre-open actions in futures doesn't necessarily translate into actual trading in the coming day’s session.

I follow the dictum, quoting Churchill that “short words are best, and the old words when short are best of all.”

 

Dow futures are DOWN -0.52% (-188 points), S&P futures are DOWN -0.24% (-11 points) and NASDAQ futures are UP +0.33% (+55 points)

 

Stock futures were mixed early Friday’s open,

European markets were lower,

Asia-Pacific markets were mixed.

 

Henry’omics:

The sector is in a more-than-normal seasonal crater coming as earnings season continues … and the market rally appeared to have slowed down from near record levels.

Investors are also keeping an eye on President Biden’s pick for the next Fed chair, which he is expected to unveil by the weekend. Many expect an even more dovish Fed if Lael Brainard is named the central bank chief, meaning it would take longer to raise interest rates or tighten policy than under Jerome Powell. <CNBC>

 

If you didn’t remember what happen at Thursday night’s close and the quarter’s “number’s” impact, you won’t be prepared for today’s session:

Thursday’s evening’s recap: “sector dives even deeper. As I stated this a.m., now eleven (11) session “dives, are we set for more – I’d wait until Monday, as Thursday just might be a marginal up day and if Friday increases the beginning of inclines.” … https://www.regmedinvestors.com/articles/12190

Q4: November, 3 positive and 11 negative close to date

  • October, 8 positive and 13 negative closes

 

Companies in my headlights – It’s your decision; I provide an idea and context:

Maintaining SELL with a Pump or No Promote:

Biostage (BSTG) closed FLAT again with 17 shares traded after Wednesday 2,889 shares traded, Tuesday’s +$0.39 to $2.99 after Monday’s FLAT at $2.60 with 35 shares traded after last Friday’s 0 shares traded.

  • Earnings release: Biostage (BSTG) had a net loss of -$800 K, or -$0.80, a $200 K decrease in grant income and a cash position of $2 m—still with NO clinical trial with a 2-year-old IND. Add in some legal negligence ... where its insurance carrier will NOT cover the terminal death suit filed.

What’s there to invest in – the “Sword of Damocles” hanging over its recent insurance company rejection of legal expense/costs of a terminal death suit against the company?

  • For a company with NO clinical trial, an a one (1) and a half year approved IND, four (4) employees and NO CRO <clinical research organization> initiation.

 

Probabilities versus aftermarket/pre-open share pricing indication moves:

SELL:

Chinook Therapeutics (KDNY) closed down -$0.23 to $16.37 and has a negative -$0.48 or -2.93% as I have been saying, the post offering flippers are active.

Intellia therapeutics (NTLA) closed up =$0.50 to $134.90 after Wednesday’s $134.40, Tuesday’s $137.50, Monday’s $133.54 and last Friday’s $132.23 with a negative -$0.90 or -0.67% pre-open indication

Regenxbio (RGNX) closed up +0.51 to $32.00 after Wednesday’s -$0.35 to $31.49, Tuesday’s $31.84 and Monday’s $31.72 with a negative -$0.10 or -0.31% pre-open indication.

Sangamo Therapeutics (SGMO) closed down again -$0.20 to $9.32 after Wednesday’s -$0.28 to $9.52 after Tuesday’s $9.80 and Monday’s $9.82 with a negative -$0.07 or -0.75%% pre-open indication.

 

BUY from SELL:

CRISPR Therapeutics (CRSP) closed down -$3.11 to $82.97 after Wednesday’s -$0.50, Tuesday’s +$1.50 and Monday’s -$3.85 with a positive +$0.60 or +0.72% pre-open indication.

 

SELL into Strength:

Applied Genetic Technologies (AGTC) closed up +$0.06 to $2.72 after Wednesday’s +$0.29 to $2.66 with a NO pre-open indication.

 

 

The BOTTOM LINE: Eleven (11) session dives; are we set for more – I’d wait until Monday, as Thursday just dropped again like a stone, Friday might increase the beginning of inclines but, any sharp inclines will be targets for the algorithms. 

I’m STILL a “beware or the cautious man” whose focus has always been “warning analysis” … earnings’ season is NOT over … my advice, trim and skim any new highs if one can!”

RMi’s daily report is a primer that may say little or a lot; yet it serves as insurance that all indications are being examined and evaluated.

WHY do I keep analyzing Biostage (BSTG): When one sees an inextricable wrong and morally repulsive scenario; it takes courage, resolve and patience to stay the course of asking the questions without response!

 

 

Opinions expressed are those of the author and are subject to change, and not intended to be a forecast of future events, a guarantee of future results, nor investment advice. Whether information or intelligence is good, bad or somewhere in between; I put into context what is relevant and useful for investors.  All investments are subject to risks. Investors should consider investment objectives.

Regulation Analyst Certification (Reg AC): The research analyst primarily responsible for the content of this report certifies the following under Reg AC: I hereby certify that all views expressed in this report accurately reflect my personal views about the subject company or companies and its or their securities. I also certify that no part of my compensation was, is or will be, directly or indirectly, related to the specific recommendations or views expressed in this report.

Henry McCusker, the editor and publisher of RegMed Investors does not hold or have positions in securities referred to in this publication.